“Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials” (2024) SKIN The Journal of Cutaneous Medicine, 8(4), p. s407. doi:10.25251/skin.8.supp.407.